Press Release

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab Emirates

POC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVID

Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome with intestinal failure (SBS-IF)

Read More